

SmartCella expands patent for the Extroducer® into the US and Japan

SmartCella Holding AB ("SmartCella") today announces that the main patent for the Extroducer® has been granted in two of the company's strategic key markets, the US and Japan. Following the European patent granted in 2024, relevant patents are now approved in all major jurisdictions.

SmartCella is a global drug delivery company pioneering innovative delivery solutions for targeted therapies. The main technology, the Extroducer®, is a modality-agnostic endovascular delivery device designed for localized delivery to hard-to-reach organs, tumors, and tissues.

The US patent for the Extroducer® was approved by the United States Patent and Trademark Office (USPTO) and in Japan, approved by Japan Patent Office. The patent covers the design of the distal part of the Extroducer®, which penetrates the vessel wall and moves smoothly towards the target location. The patent will remain valid for 20 years, which is in line with global patent standards.

Niklas Prager, CEO, comments: "Being granted patents in the US and Japan marks a significant milestone, extending the protection we have already secured in Europe into two of the world's largest life science markets. Patents are a critical part of our strategy, they give our partners the confidence to build their therapeutic programs on the Extroducer® platform, knowing their innovations are safeguarded from duplication across stages, from early clinical development through to commercialization."

Both new patents have the same claims as the patent granted by the European Patent Office (EPO) in November 2024.

Contacts

Niklas Prager, CEO +46 76 811 77 44

Nina Nornholm, Head of Communication & Investor Relations +46 708 550 356

About SmartCella

SmartCella is a global drug delivery company pioneering innovative delivery solutions for targeted therapies. The main technology, the Extroducer®, is a modality-agnostic endovascular delivery device designed for localized delivery to hard-to-reach organs, tumors, and tissues. The Extroducer® is FDA 510(k)-cleared for use in peripheral (including abdominal) tissues to inject diagnostic and therapeutic solutions into the perivascular space. It is currently in clinical investigation for additional indications. SmartCella commercializes the Extroducer® through licensing agreements with global biotech and pharma companies, enabling broad application across all development phases. The company also offers a proprietary stem cell platform for the delivery of mRNA therapeutics, featuring a proof-of-concept program focused on Osteoarthritis.

Founded in 2014, SmartCella is built on world-class research from Sweden's Karolinska Institutet.

Read more www.smartcella.com and follow SmartCella on [LinkedIn](#)